Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Neuphoria Therapeutics Inc. from 30 Jun 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Neuphoria Therapeutics Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 30 Jun 2023 to 31 Dec 2025.
  • Neuphoria Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 31 Dec 2025 was $2,434,672.
  • Neuphoria Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 31 Dec 2025 was $4,172,526, a 55% increase year-over-year.
  • Neuphoria Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2025 was $201,103, a 99% increase from 2024.
  • Neuphoria Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $15,446,978, a 31% increase from 2023.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Neuphoria Therapeutics Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,172,526 $2,434,672 +$5,666,454 01 Oct 2025 31 Dec 2025 10-Q 17 Feb 2026 2025 Q2
Q3 2025 $9,838,980 $9,857,283 -$9,637,877 -4393% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q1
Q2 2025 $201,103 $7,816,258 -$5,348,752 -217% 01 Apr 2025 30 Jun 2025 10-K 29 Sep 2025 2025 FY
Q1 2025 $5,147,649 $11,066,343 +$14,406,439 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025 2025 Q3
Q4 2024 $9,258,790 $3,231,782 +$871,557 +21% 01 Oct 2024 31 Dec 2024 10-Q 17 Feb 2026 2025 Q2
Q3 2024 $10,130,347 $219,406 +$5,316,631 +96% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q1
Q2 2024 $15,446,978 $2,467,506 01 Apr 2024 30 Jun 2024 10-K 29 Sep 2025 2025 FY
Q1 2024 $3,340,096 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025 2025 Q3
Q4 2023 $4,103,339 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025 2025 Q2
Q3 2023 $5,536,037 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q1

Neuphoria Therapeutics Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $201,103 +$15,245,875 +99% 01 Jul 2024 30 Jun 2025 10-K 29 Sep 2025 2025 FY
2024 $15,446,978 +$6,971,332 +31% 01 Jul 2023 30 Jun 2024 10-K 29 Sep 2025 2025 FY
2023 $22,418,310 01 Jul 2022 30 Jun 2023 10-K 30 Sep 2024 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.